最初的万科米辛缩水剂用于预防复发性困难菌感染:一项随机临床试验
Emily G McDonald1,2, Guillaume Butler-Laporte3, James M Brophy4
1Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Quebec, Canada.
JAMA network open
|February 27, 2026
概括
一个为期4周的万科米辛脉冲和逐渐减速疗法显示,它在预防复发性Clostridioides difficile感染 (CDI) 方面比2周的疗法优于73.8%的概率. 这种治疗可能是一种安全的选择,可以延迟或预防早期的CDI复发.
科学领域:
- 传染性疾病 传染性疾病
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 克洛斯特里迪奥伊德困难感染 (CDI) 导致严重的疾病和死亡,频繁复发 (rCDI).
- 标准治疗包括万科米辛,但rCDI仍然是一个挑战.
- 优化万科米辛治疗方案对于改善患者的治疗结果至关重要.
研究的目的:
- 为了比较一个为期4周的万科米辛脉冲和逐渐减速疗法与一个标准的为期2周的脉冲疗法来预防rCDI.
- 评估扩展范科米辛治疗方案在减少CDI复发方面的优越性.
主要方法:
- 一个平行设计,双盲,随机的临床试验,在12家加拿大医院进行.
- 在初始治疗后改善的已确认CDI的成年人被纳入.
- 参与者接受了为期2周的万科米辛脉冲,然后随机分配到4周的万科米辛缩小剂或安慰剂.
主要成果:
- 4周的万科米辛治疗方案在56日预防rCDI的概率高于73.8% (14.8%对17.7%的复发率).
- 在38天观察到复发的显著减少 (6.7%与15.4%相比),优越的概率为99%.
- 在这两组治疗中,不良事件是罕见的.
结论:
- 4周的万科米辛脉冲和逐渐减速疗法在预防早期CDI复发方面显示出有前途.
- 这种扩展的治疗方案可以作为一种安全和可访问的治疗选择.
- 进一步的研究可以验证其有效性和在CDI管理中的作用.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
798
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
798
Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Dosage Regimen: Fixed Dose
2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
314
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
314
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577


